Robert Langer
CIK 1239757 · last filed 2026-07-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RUBY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEWTON, MA 02459
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SEER | Director | 821,025 | $1.93 | $1.58M | $0 | 9 | 2026-07-30 |
| MRNA | Director | 11,481,796 | $198.85 | $2.28B | $0 | 7 | 2024-05-07 |
| Korro Bio, Inc. (FREQ) Delisted | Director | 4,458 | $14.98 | $66.8K | $0 | 5 | 2022-08-19 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | 303 | $0.70 | $212 | $0 | 2 | 2020-05-06 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | Director | 7,500 | $0.08 | $622 | -$417.2K | 6 | 2019-10-17 |
| KALA | Director | — | $0.19 | — | $0 | 2 | 2018-06-15 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 2 | 2016-06-22 |
| Ocata Therapeutics, Inc. (OCAT) Delisted | Director | 0 | — | — | $0 | 7 | 2016-02-11 |
| MILLIPORE CORP /MA (MIL) Delisted | Director | 0 | — | — | $0 | 3 | 2010-07-16 |
| WYETH (WYE) Delisted | Director | 12,505 | — | — | $0 | 5 | 2009-07-22 |
| ALSERES PHARMACEUTICALS INC /DE (ALSE) Delisted | Director | — | — | — | $0 | 2 | 2009-01-16 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Director | 950,022 | — | — | -$336.2K | 5 | 2008-08-11 |
| ALSERES PHARMACEUTICALS INC /DE (BLSI) Delisted | Director | — | — | — | $0 | 1 | 2007-03-20 |
Recent Filings · Page 5 of 10
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-01-02 | Ocata Therapeutics, Inc. (OCAT) Delisted | Grant (A) | +1,250 | $0 | EDGAR |
| 2014-10-01 | — | Grant (A) | +1,250 | $0 | |
| 2014-07-02 | — | Grant (A) | +125,000 | $0 | |
| 2014-01-03 | — | Grant (A) | +125,000 | $0 | |
| 2013-10-02 | — | Grant (A) | +125,000 | $0 | |
| 2013-07-01 | — | Grant (A) | +125,000 | $0 | |
| 2013-06-05 | — | Sell (S) | −7,500 | -$28.0K | |
| 2013-05-31 | — | Sell (S) | −7,500 | -$24.8K | |
| 2013-05-28 | — | Sell (S) | −7,500 | -$22.2K | |
| 2013-05-22 | — | Sell (S) | −7,500 | -$21.6K |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.